FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950878851> ?p ?o ?g. }

• W2950878851 abstract "Influenza virus infections remain a major and recurrent public health burden. The intrinsic ever-evolving nature of this virus, the suboptimal efficacy of current influenza inactivated vaccines, as well as the emergence of resistance against a limited antiviral arsenal, highlight the critical need for novel therapeutic approaches. In this context, the aim of this study was to develop and validate an innovative strategy for drug repurposing as host-targeted inhibitors of influenza viruses and the rapid evaluation of the most promising candidates in Phase II clinical trials. We exploited in vivo global transcriptomic signatures of infection directly obtained from a patient cohort to determine a shortlist of already marketed drugs with newly identified, host-targeted inhibitory properties against influenza virus. The antiviral potential of selected repurposing candidates was further evaluated in vitro, in vivo and ex vivo. Our strategy allowed the selection of a shortlist of 35 high potential candidates out of a rationalized computational screening of 1,309 FDA-approved bioactive molecules, 31 of which were validated for their significant in vitro antiviral activity. Our in vivo and ex vivo results highlight diltiazem, a calcium channel blocker currently used in the treatment of hypertension, as a promising option for the treatment of influenza infections. Additionally, transcriptomic signature analysis further revealed the so far undescribed capacity of diltiazem to modulate the expression of specific genes related to the host antiviral response and cholesterol metabolism. Finally, combination treatment with diltiazem and virus-targeted oseltamivir neuraminidase inhibitor further increased antiviral efficacy, prompting rapid authorization for the initiation of a Phase II clinical trial. This original, host-targeted, drug repurposing strategy constitutes an effective and highly reactive process for the rapid identification of novel anti-infectious drugs, with potential major implications for the management of antimicrobial resistance and the rapid response to future epidemic or pandemic (re)emerging diseases for which we are still disarmed." @default.
• W2950878851 created "2019-06-27" @default.
• W2950878851 creator A5003087042 @default.
• W2950878851 creator A5005935743 @default.
• W2950878851 creator A5014663814 @default.
• W2950878851 creator A5026563943 @default.
• W2950878851 creator A5032814977 @default.
• W2950878851 creator A5033309280 @default.
• W2950878851 creator A5040864885 @default.
• W2950878851 creator A5042500741 @default.
• W2950878851 creator A5043361043 @default.
• W2950878851 creator A5049793573 @default.
• W2950878851 creator A5051968820 @default.
• W2950878851 creator A5066177689 @default.
• W2950878851 creator A5074097531 @default.
• W2950878851 creator A5078194642 @default.
• W2950878851 creator A5082104321 @default.
• W2950878851 creator A5088894106 @default.
• W2950878851 creator A5089302623 @default.
• W2950878851 date "2019-01-29" @default.
• W2950878851 modified "2023-10-15" @default.
• W2950878851 title "Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures" @default.
• W2950878851 cites W1524141331 @default.
• W2950878851 cites W1541232310 @default.
• W2950878851 cites W1920811227 @default.
• W2950878851 cites W1955255689 @default.
• W2950878851 cites W1969828889 @default.
• W2950878851 cites W1970364928 @default.
• W2950878851 cites W1975957687 @default.
• W2950878851 cites W1981222054 @default.
• W2950878851 cites W1995408016 @default.
• W2950878851 cites W1998810251 @default.
• W2950878851 cites W1999406353 @default.
• W2950878851 cites W2005302698 @default.
• W2950878851 cites W2007198955 @default.
• W2950878851 cites W2018928003 @default.
• W2950878851 cites W2020743575 @default.
• W2950878851 cites W2022189028 @default.
• W2950878851 cites W2029980980 @default.
• W2950878851 cites W2031585558 @default.
• W2950878851 cites W2044340941 @default.
• W2950878851 cites W2055117508 @default.
• W2950878851 cites W2058013480 @default.
• W2950878851 cites W2062941476 @default.
• W2950878851 cites W2077138884 @default.
• W2950878851 cites W2088399547 @default.
• W2950878851 cites W2096376940 @default.
• W2950878851 cites W2103017472 @default.
• W2950878851 cites W2112872044 @default.
• W2950878851 cites W2114104545 @default.
• W2950878851 cites W2121604817 @default.
• W2950878851 cites W2122683221 @default.
• W2950878851 cites W2125200271 @default.
• W2950878851 cites W2125529503 @default.
• W2950878851 cites W2131271579 @default.
• W2950878851 cites W2138512826 @default.
• W2950878851 cites W2156564520 @default.
• W2950878851 cites W2162579298 @default.
• W2950878851 cites W2168134495 @default.
• W2950878851 cites W2256071216 @default.
• W2950878851 cites W2323326409 @default.
• W2950878851 cites W2341632992 @default.
• W2950878851 cites W2514790758 @default.
• W2950878851 cites W2803856749 @default.
• W2950878851 cites W3026172785 @default.
• W2950878851 cites W4210767115 @default.
• W2950878851 doi "https://doi.org/10.3389/fimmu.2019.00060" @default.
• W2950878851 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6361841" @default.
• W2950878851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30761132" @default.
• W2950878851 hasPublicationYear "2019" @default.
• W2950878851 type Work @default.
• W2950878851 sameAs 2950878851 @default.
• W2950878851 citedByCount "41" @default.
• W2950878851 countsByYear W29508788512019 @default.
• W2950878851 countsByYear W29508788512020 @default.
• W2950878851 countsByYear W29508788512021 @default.
• W2950878851 countsByYear W29508788512022 @default.
• W2950878851 countsByYear W29508788512023 @default.
• W2950878851 crossrefType "journal-article" @default.
• W2950878851 hasAuthorship W2950878851A5003087042 @default.
• W2950878851 hasAuthorship W2950878851A5005935743 @default.
• W2950878851 hasAuthorship W2950878851A5014663814 @default.
• W2950878851 hasAuthorship W2950878851A5026563943 @default.
• W2950878851 hasAuthorship W2950878851A5032814977 @default.
• W2950878851 hasAuthorship W2950878851A5033309280 @default.
• W2950878851 hasAuthorship W2950878851A5040864885 @default.
• W2950878851 hasAuthorship W2950878851A5042500741 @default.
• W2950878851 hasAuthorship W2950878851A5043361043 @default.
• W2950878851 hasAuthorship W2950878851A5049793573 @default.
• W2950878851 hasAuthorship W2950878851A5051968820 @default.
• W2950878851 hasAuthorship W2950878851A5066177689 @default.
• W2950878851 hasAuthorship W2950878851A5074097531 @default.
• W2950878851 hasAuthorship W2950878851A5078194642 @default.
• W2950878851 hasAuthorship W2950878851A5082104321 @default.
• W2950878851 hasAuthorship W2950878851A5088894106 @default.
• W2950878851 hasAuthorship W2950878851A5089302623 @default.
• W2950878851 hasBestOaLocation W29508788511 @default.
• W2950878851 hasConcept C103637391 @default.
• W2950878851 hasConcept C142724271 @default.
• W2950878851 hasConcept C150903083 @default.

• next